Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients
Jennifer R. Brown(Dana-Farber Cancer Institute), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Pau Abrisqueta(Universitat Autònoma de Barcelona), Coumaran Égile(AstraZeneca (United Kingdom)), Matthew S. Davids(Dana-Farber Cancer Institute), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Rodrigo Ruiz‐Soto(Deciphera Pharmaceuticals (United States))
Cited by 10
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752